Recombinant Rat cGMP-specific 3',5'-cyclic phosphodiesterase (Pde5a), partial

1. Our data showed a significant and previously undocumented upregulation of PDE5 in both rat and human BPH. PMID:26657792
2. The effects of vasodilation on plasma volume expansionhemodilution, and PDE5A expression via the renin-angiotensin-aldosterone system are reported. PMID:24068049
3. The phosphodiesterase 5A inhibitors decrease NHE-1 phosphorylation and activity through a mechanism that involves PP2A activation. PMID:21063091
4. mRNA transcript and protein levels of PDE5 in the main and first branch of the pulmonary arteries are increased by chronic hypoxia. PMID:12466227
5. PDE-5 is constitutively present in the rat uterine wall. There was no observed change in the PDE-5 protein expression throughout pregnancy. PMID:14749671
6. Kinetics of rat cellular nitric oxide/cGMP/phosphodiesterase-5 pathway PMID:15075333
7. normal rat pregnancy leads to in vivo and in vitro renal resistance to atrial natriuretic peptide, in association with heightened activity of the cGMP-specific PDE5 PMID:15100365
8. PDE5A may also play a critical role in the growth promoting effects of Angiotensin II PMID:15623434
9. Increased PDE-5 expression is involved in the decreased vascular response to nitric oxide in cirrhotic livers PMID:16545481
10. PDE5 controls the soluble cyclic GMP pool in cardiac myocytes. PMID:16651469
11. PDE5 activity limits action potential propagation in neurohypophysial axons. PMID:17690141
12. Phosphodiesterase 5A expression confirms the activity targeted inhibition by sildenafil in cardiomyocytes and hypertrophy modulation. PMID:18790048
13. PDE5 expression was not under direct androgen regulation. PMID:19338748

Show More

Hide All

UNIGENE: Rn.10861

KEGG: rno:171115

STRING: 10116.ENSRNOP00000019637